Orchestra BioMed Holdings (OBIO) Net Margin Growth (1y) (2023 - 2026)

Orchestra BioMed Holdings (OBIO) Net Margin Growth (1y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -185.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -763.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 447.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 673.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 3,097.00
7 Royalty Pharma 33.72 Bn 35.84 Bn - -392.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 2,208.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 29,636.00
10 Orchestra BioMed Holdings 265.06 Mn 80.63 Mn 63,000.00 -2.50 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -2.50 Mn
Mar 31, 2026 -1.66 Mn
Dec 31, 2025 638,352.00
Sep 30, 2025 -59,996.00
Jun 30, 2025 65,763.00
Mar 31, 2025 38,735.00
Dec 31, 2024 -159,911.00
Sep 30, 2024 346,972.00
Jun 30, 2024 -138,420.00
Mar 31, 2024 -152,607.00
Dec 31, 2023 -384,914.00
Sep 30, 2023 -435,625.00
Jun 30, 2023 11,450.00
Mar 31, 2023 -40,259.00